Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says revenue per patient has decreased due to increasing number of public-payer treatment starts and discounts required to start less-sick patients on therapy.